Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 9, Issue 3, Pages e002277
Publisher
BMJ
Online
2021-03-23
DOI
10.1136/jitc-2020-002277
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
- (2020) Victor M Corman et al. Eurosurveillance
- Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China
- (2020) L. Zhang et al. ANNALS OF ONCOLOGY
- TERAVOLT: Thoracic Cancers International COVID-19 Collaboration
- (2020) Jennifer G. Whisenant et al. CANCER CELL
- Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan
- (2020) Xiaochen Li et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- The UK Coronavirus Cancer Monitoring Project: protecting patients with cancer in the era of COVID-19
- (2020) Iris Anil et al. LANCET ONCOLOGY
- Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis
- (2020) Giuseppe Lippi et al. PROGRESS IN CARDIOVASCULAR DISEASES
- D-dimer is Associated with Severity of Coronavirus Disease 2019: A Pooled Analysis
- (2020) Giuseppe Lippi et al. THROMBOSIS AND HAEMOSTASIS
- Patients with cancer appear more vulnerable to SARS-COV-2: a multi-center study during the COVID-19 outbreak
- (2020) Mengyuan Dai et al. Cancer Discovery
- Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis
- (2020) Giuseppe Lippi et al. CLINICA CHIMICA ACTA
- Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China
- (2020) J. Zhang et al. CLINICAL MICROBIOLOGY AND INFECTION
- Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients.
- (2020) David J Pinato et al. Cancer Discovery
- Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe
- (2020) David J. Pinato et al. Cancers
- Hyperferritinemia in critically ill COVID-19 patients – Is ferritin the product of inflammation or a pathogenic mediator?
- (2020) Jenifer Gómez-Pastora et al. CLINICA CHIMICA ACTA
- The REDCap consortium: Building an international community of software platform partners
- (2019) Paul A. Harris et al. JOURNAL OF BIOMEDICAL INFORMATICS
- The systemic inflammatory response as a source of biomarkers and therapeutic targets in hepatocellular carcinoma
- (2019) Chandan Sanghera et al. LIVER INTERNATIONAL
- The prognostic significance of the prognostic nutritional index in cancer: a systematic review and meta-analysis
- (2014) Kaiyu Sun et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- The systemic inflammation-based neutrophil–lymphocyte ratio: Experience in patients with cancer
- (2013) Graeme J.K. Guthrie et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer
- (2012) Hyuk-Chan Kwon et al. BIOMARKERS
- An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study
- (2011) M J Proctor et al. BRITISH JOURNAL OF CANCER
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support
- (2008) Paul A. Harris et al. JOURNAL OF BIOMEDICAL INFORMATICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started